Drug Profile
Lu AF11167
Alternative Names: Lu-AF-11167Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Lundbeck A/S
- Class Antipsychotics
- Mechanism of Action Phosphodiesterase 10A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Schizophrenia
- No development reported Neurodegenerative disorders; Psychotic disorders
Most Recent Events
- 28 Oct 2022 No recent reports of development identified for phase-I development in Schizophrenia(In volunteers) in United Kingdom (PO, Tablet)
- 27 Sep 2022 No development reported - Phase-II for Schizophrenia in Bulgaria, Czech Republic, Germany, Poland, Ukraine, Hungary (PO) (NCT03793712)
- 03 Sep 2020 Lundbeck terminates a phase-II trial in Schizophrenia in Bulgaria, Czech Republic, Estonia, Germany, Hungary, Latvia, Poland, and Ukraine (PO) due to lack of efficacy based on the interim analysis of the 17972A study (EudraCT2018-002708-15) (NCT03929497)